0.7812
price up icon2.52%   0.0192
 
loading
Schlusskurs vom Vortag:
$0.762
Offen:
$0.76
24-Stunden-Volumen:
131.83K
Relative Volume:
0.66
Marktkapitalisierung:
$59.60M
Einnahmen:
$9.53M
Nettoeinkommen (Verlust:
$-44.61M
KGV:
-0.8585
EPS:
-0.91
Netto-Cashflow:
$-38.32M
1W Leistung:
-1.24%
1M Leistung:
-20.66%
6M Leistung:
-53.50%
1J Leistung:
-49.92%
1-Tages-Spanne:
Value
$0.7411
$0.7955
1-Wochen-Bereich:
Value
$0.72
$0.8849
52-Wochen-Spanne:
Value
$0.45
$2.26

Cue Biopharma Inc Stock (CUE) Company Profile

Name
Firmenname
Cue Biopharma Inc
Name
Telefon
617-949-2680
Name
Adresse
40 GUEST STREET, BOSTON, MA
Name
Mitarbeiter
41
Name
Twitter
@cuebiopharma
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
CUE's Discussions on Twitter

Vergleichen Sie CUE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CUE
Cue Biopharma Inc
0.7812 59.60M 9.53M -44.61M -38.32M -0.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-03-13 Eingeleitet Jefferies Buy
2023-06-26 Fortgesetzt Oppenheimer Outperform
2022-11-21 Eingeleitet Piper Sandler Overweight
2022-01-13 Eingeleitet H.C. Wainwright Buy
2022-01-03 Eingeleitet Craig Hallum Buy
2020-11-24 Eingeleitet Berenberg Buy
2020-04-09 Eingeleitet Stifel Buy
2020-01-28 Eingeleitet BTIG Research Buy
2020-01-22 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten

pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 17, 2025

Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals

Apr 17, 2025
pulisher
Apr 16, 2025

Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech

Apr 15, 2025
pulisher
Apr 15, 2025

Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq

Apr 15, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Form 424B5 Cue Biopharma, Inc. - StreetInsider

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Proposed Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma to Host Business Update Call and Webcast - Enidnews.com

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Major Biotech Deal: Cue Biopharma Secures $357M Partnership for Revolutionary Autoimmune Treatment - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

‘Buy These Two Chip Stocks Ahead of a Recession,’ Says Citi - The Globe and Mail

Apr 11, 2025
pulisher
Apr 11, 2025

S&P 500 jumps 1.8% as Wall Street closes a chaotic and historic week - The Globe and Mail

Apr 11, 2025
pulisher
Apr 11, 2025

Can Spotify’s (SPOT) Ad Business Hit the Right Notes in 2025? - The Globe and Mail

Apr 11, 2025
pulisher
Apr 10, 2025

Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail

Apr 10, 2025
pulisher
Apr 10, 2025

EXL Schedules First Quarter 2025 Financial Results Conference Call - The Globe and Mail

Apr 10, 2025
pulisher
Apr 10, 2025

Will Tariffs Destroy This Clothing Giant? - The Globe and Mail

Apr 10, 2025
pulisher
Apr 09, 2025

United Community Banks, Inc. Announces Date for First Quarter 2025 Earnings Release and Conference Call - The Globe and Mail

Apr 09, 2025
pulisher
Apr 09, 2025

Vision Marine Technologies Strengthens Innovation with New Patent Filing for Secure Vessel Connectivity - The Globe and Mail

Apr 09, 2025

Finanzdaten der Cue Biopharma Inc-Aktie (CUE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):